Dr. Shaorong Yu 于韶荣
Chief Physician, Associate Professor
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lung cancer.
Dr. Yu holds an MD and completed postdoctoral training. As Deputy Director of the Medical Oncology Department at Jiangsu Cancer Hospital, Dr. Yu focuses on lung cancer. Dr. Yu is a member of ASCO and ESMO. Dr. Yu has led grants from the National Natural Science Foundation of China and published over ten SCI papers as first author.
Professional roles
- Member, Chemotherapy Professional Committee, China Anti-Cancer Association
- Young Committee Member, National Clinical Application of Anti-tumor Drugs
- Director, Jiangsu Society of Environmental Mutagens
- Member, Translational Medicine Branch, Jiangsu Immunological Society
Name order: in Chinese the family name comes first (Yu Shaorong). Papers usually list the name as Shaorong Yu or Yu S.
Selected publications
52 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Genes Dis, 2026 (senior author): Targeting PAK1 suppresses tumor progression by promoting mRNA decay of oncogenic factors and enhancing chemotherapeutic efficacy in colorectal cancer. PubMed 41459112
- Cancer Lett, 2026 (senior author): HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8(+) T cell glutamine metabolism via KIR3DL3 interaction. PubMed 41391682
- J Thorac Dis, 2025 (senior author): Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study. PubMed 40083528
- J Thorac Dis, 2024 (senior author): Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study. PubMed 38617775
- Technol Cancer Res Treat, 2024 (senior author): Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis. PubMed 38258375
- J Thorac Oncol, 2024 (first author): Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial". PubMed 38185511
- Front Oncol, 2022 (senior author): Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study. PubMed 36698393
- Pathol Res Pract, 2020 (senior author): B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma. PubMed 32853956
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion